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We thank dr. Lucas for her comments regarding our ar-
ticle in which we described patients with heart failure
with preserved ejection fraction (HFpEF) and low levels
of natriuretic peptides. In this article [1], we described that
HFpEF patients with relatively low B-type natriuretic
peptide (BNP) levels have strikingly similar clinical char-
acteristics as HFpEF patients with elevated BNP levels,
except for BMI, which was significantly higher in the first
group. Clinicians might expect that low BNP levels are
associated with low risk of adverse events, but, as recently
observed in another study [2], NP-proBNP and BNP are
not the ideal markers to identify low-risk patients.
The hypothesis, shared by dr. Lucas, that the stiff left
atrial syndrome might explain the low BNP levels observed
in HFpEF patients is interesting. The stiff left atrium has
mostly been described after ablation therapy for atrial fib-
rillation (AF) [3, 4]. However, we agree that also in heart
failure, atrial tissue may remodel and become stiff. It has in-
deed been suggested that heart failure patients with a longer
duration of AF exhibit advanced remodelling of the atrial
tissue, in which atrial cardiomyocytes are replaced by fi-
brotic tissue, a hallmark of remodelling [5]. The remaining
atrial tissue no longer produces natriuretic peptides, with
pseudo-low natriuretic peptide levels as a result [6].
Reply to the letter ‘Stiff left atrial syndrome as another cause for
heart failure with preserved ejection fraction and normal BNP
levels’.
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However, in our study we observed a comparable preva-
lence of AF in both groups (BNP <100 pg/mL vs. BNP
>100 pg/mL, 50% AF in both groups), suggesting the sever-
ity of atrial remodelling is equal. Further, advanced atrial
remodelling would most likely be accompanied by higher
levels of inflammatory and fibrotic biomarkers. But the lev-
els of galectin-3, a fibrotic protein associated with worse
outcome [7], and interleukin-6, an inflammatory biomarker,
were comparable between both groups.
Preferably, we would have assessed cardiac and atrial
dimensions by echocardiography, but, unfortunately, we do
not have these data in the COACH database and acknowl-
edge this as a limitation of our study.
So, based on the data presented, we cannot demonstrate
evidence that the low BNP levels in our study were due to
progressed atrial remodelling. But we agree that studying
the left atrium is of importance in HF patients with paroxys-
mal or persistent AF and in patients who have pseudo-low
BNP levels. Indeed, stiffening of the left atrium may clini-
cally be under-recognized and more awareness is needed.
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